Ann: Appendix 4C - Quarterly - 30 June 2023, page-7

A very strange announcement at a time when the primary objective should be building investor confidence.

Key takeaways

1. No mention of DX3.
2. No mention of the pending exercise of PABO and PABOA options. I think they have given up on any financing from this source.
3. No indicative date for commencement of the DX1 Phase 1 clinical trail.
4. And most galling for shareholders under Item 6.1 it would appear they have paid the good Dr a bonus from shareholders' funds of approximately $94,000 in a year where the company went backwards, and shareholders have lost over 50% of their value. BOD please explain. How could you be so dismissive of shareholders to whom you hold a duty of care!!!!!

IMO
DYOR

Clare